Communiqués Photocure ASA

Actions

PHO

NO0010000045

Produits pharmaceutiques

PEA

PEA/PME

Temps réel Oslo Bors 09:13:25 27/08/2026			Varia. 5j.	Varia. 1 janv.
54,70 ^NOK	+0,37 %		+1,11 %	-23,39 %

16/08	Photocure entrevoit un fort potentiel dans le projet de reclassification des systèmes de cystoscopie par la FDA	MT
14/08	Photocure ASA : la FDA propose de reclasser les systèmes de cystoscopie en lumière bleue de la classe III à la classe II	CI

Communiqués

17/08	Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II	AQ
14/08	Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II	AQ
11/08	Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.	AQ
07/08	Photocure ASA: Notification of primary insider transactions	AQ
07/08	Photocure ASA - Share option grant to members of the board of directors	AQ
04/08	Photocure ASA: Asieris counterclaim on milestone payment arbitration	AQ
29/07	Photocure ASA - Share option grant	AQ
29/07	Photocure ASA: Results for the second quarter of 2026	AQ
23/07	Photocure : initiates arbitration in partial milestone payment case with Asieris Pharmaceuticals	PU
22/07	Photocure ASA: Invitation to presentation of second quarter 2026 financial results	AQ
14/07	Photocure ASA - Share option grant	AQ
30/06	Photocure ASA - CFO transition	AQ
26/06	Photocure ASA: Annual general meeting held	AQ
08/06	Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer	AQ
05/06	Photocure ASA - Notice of the Annual General Meeting 26 June 2026	AQ
04/06	Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics	AQ
18/05	AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study	AQ
07/05	Photocure ASA: Results for the first quarter of 2026	AQ
04/05	New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer	AQ
30/04	Photocure ASA: Invitation to presentation of first quarter 2026 financial results	AQ
27/04	Photocure ASA: Annual Report 2025	AQ
20/04	Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals	AQ
17/04	Photocure : Asieris publishes Annual Report and shares Market approval of Richard Wolf System blue equipment in China	PU
13/04	Financial calendar	AQ
13/04	Photocure ASA: Update on Regulatory Classification for OAY Equipment	AQ